gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ADMAHealthcareBiotechnology

ADMA Biologics, Inc. (ADMA)

$10.48−5.67%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$11.11▼ 27.72% in range
Nov 3, 2025Low $7.60 · High $20.38Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

ADMA Biologics closed at $10.48 on Nov 4, down 5.67%, 48.6% below its 52-week closing high. Volume of 13.4M shares was 4.70× its 20-day average (well above normal).

Split-adjusted performance: +2.9% over one month, +4.0% over six months, -31.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $124.39M, up 2.0% from a year earlier, with a net margin of 30.4%.

Short interest was 19.5M shares at the Oct 15 settlement, down 5.2% from the prior report (9.1% of float, 6.5 days to cover).

Market cap$2.35B224.0M shares
Revenue · quarter$124.4M+2.0% YoY
Diluted EPS$0.16+14.3% YoY
P/E · TTM13.9×P/S 4.6×
Net margin30.4%Gross 69.4%
Dividend yieldNone
52-week range7.60 – 20.38−48.6% from high
Volume13.4M4.70× 20-day avg
Volatility · 60d40.3%Annualised
Short % of float9.1%6.6 days to cover
Net cash-$60.6MCash $136.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.1%1M +2.9%3M +4.2%6M +4.0%YTD −42.5%1Y −31.8%3Y +217.6%5Y +676.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum68
Revenue growth40
Net margin87
Value (low P/E)62
Size81

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short19.5M−5.2% vs prior
Days to cover6.6Settled Oct 15
% of float9.1%
Short vol. 10d50.6%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ADMAADMA Biologics$10.48−5.67%+4.0%+2.0%30.4%13.9$2.35B
VCELVericel$45.48+10.68%+23.7%+22.5%2.8%96.2$2.33BCompare
RXRXRecursion Pharmaceuticals$3.88+5.43%+13.1%+258.5%−641.6%—$2.32BCompare
COAGHemab Therapeutics Holdings$45.09+4.62%————$2.11BCompare
BCRXBioCryst Pharmaceuticals$8.24−3.85%−6.7%+33.6%35.9%—$2.11BCompare
VIRVir Biotechnology$11.77+4.90%+14.4%+19582.5%33.5%—$1.99BCompare
REPLReplimune Group$20.69+0.19%+501.5%———$1.96BCompare
BEAMBeam Therapeutics$27.79+5.54%−14.1%−94.2%−25036.3%—$2.87BCompare
MAZEMaze Therapeutics$33.38+3.50%+26.1%———$1.85BCompare

News about ADMA Biologics

All news →
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research · 5d agoNeutralADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswire Inc. · Oct 28, 2026NeutralAdma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth KnowingZacks Investment Research · Oct 20, 2026▲ PositiveAdma Biologics (ADMA) Advances While Market Declines: Some Information for InvestorsZacks Investment Research · Oct 8, 2026▲ PositiveADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research · Oct 8, 2026Neutral

Quick answers

What does ADMA Biologics do?
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment.
What is ADMA's market cap?
$2.35B, based on the Nov 4 close of $10.48.
What is ADMA's P/E ratio?
13.9× trailing-twelve-month earnings of $168.96M.
Does ADMA Biologics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ADMA is sold short?
19.5M shares, 9.1% of float, as of Oct 15, 2026.
What sector is ADMA in?
Healthcare, in the Biotechnology industry.

About ADMA Biologics

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

HQ: Ramsey, NJ647 employeesListed Oct 17, 2013admabiologics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology